185 related articles for article (PubMed ID: 2758413)
1. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients.
Hajto T; Hostanska K; Gabius HJ
Cancer Res; 1989 Sep; 49(17):4803-8. PubMed ID: 2758413
[TBL] [Abstract][Full Text] [Related]
2. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration.
Kunze E; Schulz H; Gabius HJ
J Cancer Res Clin Oncol; 1998; 124(2):73-87. PubMed ID: 9654190
[TBL] [Abstract][Full Text] [Related]
3. [Detection and quantitative determination of lectins and viscotoxins in mistletoe preparations].
Jordan E; Wagner H
Arzneimittelforschung; 1986 Mar; 36(3):428-33. PubMed ID: 3707660
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of iscador: a Viscum album preparation.
Hajto T
Oncology; 1986; 43 Suppl 1():51-65. PubMed ID: 2433654
[TBL] [Abstract][Full Text] [Related]
5. Further refinement of the description of the ligand-binding characteristics for the galactoside-binding mistletoe lectin, a plant agglutinin with immunomodulatory potency.
Galanina OE; Kaltner H; Khraltsova LS; Bovin NV; Gabius HJ
J Mol Recognit; 1997; 10(3):139-47. PubMed ID: 9408830
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of immunoactive mistletoe lectin-I.
Beuth J
Anticancer Drugs; 1997 Apr; 8 Suppl 1():S53-5. PubMed ID: 9179369
[TBL] [Abstract][Full Text] [Related]
7. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe?
Gabius HJ; Gabius S; Joshi SS; Koch B; Schroeder M; Manzke WM; Westerhausen M
Planta Med; 1994 Feb; 60(1):2-7. PubMed ID: 8134410
[TBL] [Abstract][Full Text] [Related]
8. [Comparative studies on the immunoactive action of galactoside-specific mistletoe lectin. Pure substance compared to the standardized extract].
Beuth J; Ko HL; Tunggal L; Geisel J; Pulverer G
Arzneimittelforschung; 1993 Feb; 43(2):166-9. PubMed ID: 7681287
[TBL] [Abstract][Full Text] [Related]
9. Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response.
Kunze E; Schulz H; Adamek M; Gabius HJ
J Cancer Res Clin Oncol; 2000 Mar; 126(3):125-38. PubMed ID: 10741906
[TBL] [Abstract][Full Text] [Related]
10. The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells.
Gabius HJ; Walzel H; Joshi SS; Kruip J; Kojima S; Gerke V; Kratzin H; Gabius S
Anticancer Res; 1992; 12(3):669-75. PubMed ID: 1622124
[TBL] [Abstract][Full Text] [Related]
11. Structure and properties of polysaccharides from Viscum album (L.).
Jordan E; Wagner H
Oncology; 1986; 43 Suppl 1():8-15. PubMed ID: 3808577
[TBL] [Abstract][Full Text] [Related]
12. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients.
Heiny BM; Beuth J
Anticancer Res; 1994; 14(3B):1339-42. PubMed ID: 8067703
[TBL] [Abstract][Full Text] [Related]
13. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo.
Hajto T; Hostanska K; Weber K; Zinke H; Fischer J; Mengs U; Lentzen H; Saller R
Nat Immun; 1998; 16(1):34-46. PubMed ID: 9789123
[TBL] [Abstract][Full Text] [Related]
14. Studies on the standardization of mistletoe preparations.
Wagner H; Jordan E; Feil B
Oncology; 1986; 43 Suppl 1():16-22. PubMed ID: 3027640
[TBL] [Abstract][Full Text] [Related]
15. Respiratory burst of human polymorphonuclear leukocytes in response to the galactoside-specific mistletoe lectin.
Braun JM; Gemmell CG; Beuth J; Ko HL; Pulverer G
Zentralbl Bakteriol; 1995 Nov; 283(1):90-4. PubMed ID: 9810649
[TBL] [Abstract][Full Text] [Related]
16. Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems.
Beuth J; Ko HL; Gabius HJ; Pulverer G
In Vivo; 1991; 5(1):29-32. PubMed ID: 1932621
[TBL] [Abstract][Full Text] [Related]
17. Carbohydrate-binding proteins (plant/human lectins and autoantibodies from human serum) as mediators of release of lysozyme, elastase, and myeloperoxidase from human neutrophils.
Timoshenko AV; Kayser K; Drings P; André S; Dong X; Kaltner H; Schneller M; Gabius HJ
Res Exp Med (Berl); 1995; 195(3):153-62. PubMed ID: 8570910
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cytotoxic proteins from mistletoe (Viscum album L.).
Jung ML; Baudino S; Ribéreau-Gayon G; Beck JP
Cancer Lett; 1990 May; 51(2):103-8. PubMed ID: 2344587
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties.
Holtskog R; Sandvig K; Olsnes S
Oncology; 1988; 45(3):172-9. PubMed ID: 3368193
[TBL] [Abstract][Full Text] [Related]
20. Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts.
Gabius HJ; Darro F; Remmelink M; André S; Kopitz J; Danguy A; Gabius S; Salmon I; Kiss R
Cancer Invest; 2001; 19(2):114-26. PubMed ID: 11296616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
